• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Isoleucine–tRNA ligase, cytoplasmic (IARS), Truncated

ACP20167

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP20167 Target NameIARS
Target SynonymsIARS1; IARS; Isoleucine--tRNA ligase; cytoplasmic; EC 6.1.1.5; Isoleucyl-tRNA synthetase; IRS; IleRSFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP41252
Background Information
  • Uniprot Id

    P41252

  • Target Species

    Human

  • Target Name

    IARS1

  • Target Full Name

    Isoleucine--tRNA ligase, cytoplasmic

  • Target Function

    Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA.

  • Target Involvement

    Growth retardation, intellectual developmental disorder, hypotonia, and hepatopathy (GRIDHH)

  • Target Subcellular Location

    Cytoplasm. Cytoplasm, cytosol.

  • Target Protein Families

    Class-I aminoacyl-tRNA synthetase family

  • Target Tissue Specificity

    Expressed in liver and muscle (at protein level).

  • Target Research Area

    Epigenetics and Nuclear Signaling

  • Target Synonyms

    IARS1; IARS; Isoleucine--tRNA ligase; cytoplasmic; EC 6.1.1.5; Isoleucyl-tRNA synthetase; IRS; IleRS

Inquire Recombinant Human Isoleucine–tRNA ligase, cytoplasmic (IARS), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification